Agilent - Breakthroughs in Immunotherapy- 2019 - 31

Breakthroughs in Immunotherapy

enabling us to complete this work in less than a month. We are
also able to add reagents to the experiments while they're in
progress and assess the effects on cancer killing in real time.
Dr. Golubovskaya: Being label-free, real-time, dose-dependent,
and time-dependent are the most important characteristics for
immune cell-mediated killing assays. The xCELLigence technology is very good because it is measuring the cytotoxicity of
the T cells and the death of the target cancer cells in real time.
GEN: What are the specific advantages of the xCELLigence
instrument and the benefits of a label-free assay method?
How would you describe its role in early-stage research and
commercial product development?
Dr. Overstreet: I've had requests from scientists throughout our
organization interested in using the instrument because it is so
data rich with its real-time analysis. The label-free aspect of the
xCELLigence platform streamlines your workflow. Also, the platform's nondestructive analysis allows you to perform any kind of
orthogonal readouts to assess the antitumor responsiveness of
your T cells, such as flow cytometry or cytokine analysis.
Combining this instrument with some of the scientific infrastructure and human immunology model development that we've done
here, a lot of people are really excited about our approach and our
ability to test molecules in a relevant human cell-based system.
We hope this will ultimately improve our preclinical modeling and
strengthen our rationale for taking molecules into the clinic.
Dr. Bamdad: We are working with the Fred Hutchison Cancer
31

| GENengnews.com

Vita Golubovskaya, Ph.D.
Director of Research and Development
ProMab Biotechnologies

"The xCELLigence technology is
very good because it is measuring
the cytotoxicity of the T cells and the
death of the target cancer cells in
real time."

http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019